Walleye Capital
LBPH

Walleye Capital’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Walleye Capital’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-198,310
Closed -$4.28M – 6218
2024
Q1 		$4.28M Buy
198,310
+158,946
+404% +$3.47M 0.01% 1411
2023
Q4 		$237K Buy
+39,364
New +$196K ﹤0.01% 3562

Other funds holding LBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Walleye Capital's LBPH Position: Q2 2024 in Review

Walleye Capital sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q2 2024, closing a stake of 198,310 shares — an estimated $4.28M sold.

Walleye Capital first reported a position in LBPH in Q4 2023 and held it in 2 quarters. The position peaked at $4.28M in Q1 2024. 100 funds tracked by Wall St. Rank hold LBPH as of Q2 2024.

  • Walleye Capital reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 198,310 Longboard Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $4.28M.
  • Walleye Capital first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Walleye Capital's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $4.28M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.